Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis—Mechanistic Insights into Anemia of Inflammation and Its Treatment
Физиология и воспаление-обусловленная патофизиология гомеостаза железа: механистические представления об анемии воспаления и ее лечении
2021-10-22
SCID: 54.1/pdaaxpk6
Discuss with AI
anemia of inflammationerythropoietin-stimulating agentshepcidinhypoxia-inducible factor stabilizersiron homeostasis
Figures from the paper
Abstract (AI)
Anemia is very common in patients with inflammatory disorders. Its prevalence is associated with severity of the underlying disease, and it negatively affects quality of life and cardio-vascular performance of patients. Anemia of inflammation (AI) is caused by disturbances of iron metabolism resulting in iron retention within macrophages, a reduced erythrocyte half-life, and cytokine mediated inhibition of erythropoietin function and erythroid progenitor cell differentiation. AI is mostly mild to moderate, normochromic and normocytic, and characterized by low circulating iron, but normal and increased levels of the storage protein ferritin and the iron hormone hepcidin. The primary therapeutic approach for AI is treatment of the underlying inflammatory disease which mostly results in normalization of hemoglobin levels over time unless other pathologies such as vitamin deficiencies, true iron deficiency on the basis of bleeding episodes, or renal insufficiency are present. If the underlying disease and/or anemia are not resolved, iron supplementation therapy and/or treatment with erythropoietin stimulating agents may be considered whereas blood transfusions are an emergency treatment for life-threatening anemia. New treatments with hepcidin-modifying strategies and stabilizers of hypoxia inducible factors emerge but their therapeutic efficacy for treatment of AI in ill patients needs to be evaluated in clinical trials.
Key Findings
1
Anemia of inflammation results from macrophage iron retention, shortened erythrocyte survival, and cytokine-mediated suppression of erythropoietin and erythroid differentiation.
2
Anemia prevalence increases with inflammatory disease severity and impairs patients’ quality of life and cardiovascular performance.
3
Iron supplementation or erythropoiesis-stimulating agents may be considered when inflammation or anemia persists; hepcidin-targeting and hypoxia-inducible-factor therapies require clinical evaluation.
4
The condition is typically mild-to-moderate, normocytic, and normochromic, with low circulating iron despite normal or elevated ferritin and hepcidin.
5
Treating the underlying inflammatory disease is the primary therapy and generally normalizes hemoglobin unless vitamin deficiency, bleeding-related iron deficiency, or renal insufficiency coexist.
Research Object
anemia of inflammation and its associated iron-homeostasis disturbances in patients with inflammatory disorders
Research Subject
the pathophysiological mechanisms of anemia of inflammation and the therapeutic effects of iron supplementation, erythropoietin-stimulating agents, hepcidin-modifying strategies, and hypoxia-inducible-factor stabilizers
Publication Details
Publication Date
2021-10-22
Journal
Publisher
ISSN
Cited by
183
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest